Solu Therapeutics to Present Data on STX-0712 for Leukemia at ASH
02 Dec 2024 //
PR NEWSWIRE
Solu Appoints Sergio Santillana As Chief Medical Officer
10 Sep 2024 //
PR NEWSWIRE
Solu Therapeutics Appoints Michael Boretti, Ph.D., as Chief Business Officer
19 Mar 2024 //
BUSINESSWIRE
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and CEO
11 Sep 2023 //
BUSINESSWIRE
Solu Therapeutics Announces Presentation at ACS Symposium
15 Aug 2023 //
BUSINESSWIRE
Solu Therapeutics Debuts with $31 Million in Seed Funding
01 Aug 2023 //
BUSINESSWIRE